Cathepsin A (CatA) is a serine carboxypeptidase distributed between lysosomes, cell membrane, and extracellular space. Several peptide hormones including bradykinin and angiotensin I have been described as substrates. Therefore, the inhibition of CatA has the potential for beneficial effects in cardiovascular diseases. Pharmacological inhibition of CatA by the natural product ebelactone B increased renal bradykinin levels and prevented the development of salt-induced hypertension. However, so far no small molecule inhibitors of CatA with oral bioavailability have been described to allow further pharmacological profiling. In our work we identified novel β-amino acid derivatives as inhibitors of CatA after a HTS analysis based on a project adapted fragment approach. The new inhibitors showed beneficial ADME and pharmacokinetic profiles, and their binding modes were established by X-ray crystallography. Further investigations led to the identification of a hitherto unknown pathophysiological role of CatA in cardiac hypertrophy. One of our inhibitors is currently undergoing phase I clinical trials.
Light work: The light‐harvesting marine C37 carotenoid peridinin was synthesized from (+)‐diethyl tartrate and (−)‐actinol. Key transformations were the differential reduction of an ester‐containing Weinreb amide, an E‐selective olefination by an Ando‐type bromophosphonate, the anti‐selective β‐elimination establishing the C1′C5 bond Z selectively, and a cis→trans isomerization of the C6′C7′ bond (see picture).
We describe an efficient total synthesis of the sesquiterpenes (±)-β-isocomene and (±)-isocomene using a Lewis acid-promoted [3 + 2] cycloaddition of allyl-tert-butyldiphenylsilane as the key-step.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.